Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 21 for “"sRANKL"”.
-
Αλληλεπιδράσεις μυελωματικών κυττάρων και κυττάρων στρώματος μυελού των οστών: συσχέτιση των ευρημάτων με την παθογένεια, την κλινική ετερογένεια και την πρόγνωση του πολλαπλού μυελώματος
… determine serum levels of s-synd-1, MIP-1α, OPG, sRANKL, IGF-1, VEGF and TGF-β1 in untreated myeloma patients and to correlate them with parameters of disease activity and prognosis. Patients and Methods: Frosen sera from 102 untreated MM patients, 18 subjects with monoclonal gammopathy of …
-
Effect of smoking on concentrations of RANKL and OPG in human gingival crevicular fluid.
… was to compare the levels of soluble RANKL (sRANKL), OPG and their relative ratio in GCF among periodontitis patients with varying smoking histories. Material and Methods: GCF samples were collected from 149 periodontitis patients who were never smokers (n=58), former smokers (n=39) and …
-
Επίδραση της θεραπείας με διφωσφονικά στον οστικό μεταβολισμό σε παιδιά με ατελή αστεογένεση
… and receptor activator of nuclear factor-κB (sRANKL) and osteoprotegerin (OPG) levels.Ten children with a clinical diagnosis of OI, median age 8.12 years, were included in the study. The patients received pamidronate infusions on two consecutive days, administered at age-dependent intervals of …
-
Συγκριτική μελέτη, σε μετεμμηνοπαυσιακές γυναίκες, της in vivo επίδρασης στο σύστημα των κυτταροκινών οστεοπροτεγερίνης-RANKL, φαρμακευτικών παραγόντων με διαφορετική δράση στο δίπολο οστεοκλάστης - οστεοβλάστης
… to the control group. On the other hand, sRANKL levels were decreased significantly during the six months ofthe study in all three studied groups. The OPG / RANKL ratio, thought to reflect the net effect ofboth cytokines on osteoclast activity, increased gradually in all three groups, as a …
-
Ιδιοπαθής υπερασβεστιουρία στην παιδική ηλικία: συσχέτιση με το μεταβολισμό των οστών
… of osteoclastogenesis osteoprotegerin (OPG) and sRANKL (soluble kB ligand receptor activator) in patients with IH. The aim of our study was to evaluate serum biochemical markers of bone formation, alkaline phosphatase (ALP) and osteocalcin (OC), and of bone resorption of degraded fragments of …
-
Μοριακοί και βιοχημικοί δείκτες σε γυναίκες με σύνδρομο πολυκυστικών ωοθηκών (pcos)
… gene polymorphisms, serum biomarkers OPG and sRANKL as cardiovascular biomarkers, hormones (DHEAS, SHBG, testosterone, E2, LH, FSH, prolactin, insulin, 17-OH progesterone) and clinical characteristics as well (amenorrhea, oligomenorrhea, dysmenorrhea, acne, hirsutism, oily skin).STUDY DESIGN: …
-
Μελέτη οστικού μεταβολισμού στο πολλαπλούν μυέλωμα
… levels of activation markers of osteoclasts (sRANKL, sRANKL/OPG, CCL-3, OPN) and bone resorption (CTX, NTX, TRACP-5b) and partly suppressed osteoblast function and bone formation, as reflected by the elevated values of inhibitors of osteoblasts (Dkk-1, activin-A, sclerostin) and the reduced …
-
Επίδραση της θεραπείας με διφωσφωνικά στα επίπεδα του ορού των κυτταροκινών , σε ασθενείς με οστεολυτικές μεταστάσεις: συσχέτιση με την κλινική εικόνα της νόσου και την συνολική επιβίωση
… ●Receptor activator of nuclear factor κB ligand (sRANKL)●Osteoprotegerin (OPG) ●Osteocalcin(OC)●Osteopontin(OPN)● Tartrate-resistant acid phosphatase isoform 5b(TRACP-5b)● C-terminal crosslinking telopeptide of type I collagen (CTX) ●Bone alkaline phosphatase (BALP)●C-terminal propeptide of type I …
-
Συσχέτιση του πάχους του έσω-μέσου χιτώνα των καρωτίδων με παράγοντες προφλεγμονώδους διεργασίας σε παιδιά με σακχαρώδη διαβήτη τύπου 1
… and laboratory measurements, including serum OPG,sRANKL and CIMT, as well as traditional biochemical cardiometabolic parameters.Results: Anthropometric, laboratory, and CIMT measurements were not different between youngsterswith T1D and matched controls. However, patients with long diabetes …
-
Παράγοντες που οδηγούν σε έκτοπη οστεοποίηση μετά από κρανιοεγκεφαλική κάκωση
… activator of nuclear factor kappa-B ligand (sRANKL), N-MID osteocalcin, S100 and the cytokines IL-2, IL-4, IL-6, IL-10, INF-γ and TNF-a. All measured molecules participate directly or indirectly in bone formation and metabolism and in inflammation. Our 55 patients were divided and studied in …
-
Μελέτη της ετερότοπης οστεοποίησης νευρογενούς αιτιολογίας
… along with time. The system osteoprotegerin - sRANKL presents the following characteristics: osteoprotegerin is measurable and increases towards the end of measurements. sRANKL on the contrary is not measurable at any time following traumatic brain injury. Consequently, Traumatic Brain Injury …
-
Μελέτη αγγειογέννεσης και οστικού μεταβολισμού στη μακροσφαιριναιμία waldenstrom
… demonstrate that serum MIP-1a , angiopoietin-2, sRANKL and other cytokines correlate with increased disease activity. Increased bone marrow microvessel density and increased bone marrow PGM1 number also correlate with increased disease activity, thus been lower in patients with IgM MGUS and …
-
Συσχέτιση επιπέδων SRANKLκαι OPG στον ορό του αίματος και στο υγρό της ουλοδοντικής σχισμής και βαθμού ριζικής απορρόφησης κατά την ορθοδοντική θεραπεία
… in a rat model of the levels of OPG and sRANKL in blood and in gingival crevicular fluid (GCF) in relation to the degree of root resorption during orthodontic tooth movement using healthy experimental animals and a carefully planned and organized experimental design. For this purpose …
-
Involvement of Nitric Oxide in Osteoclastogenesis and Orthodontic Tooth Movement
… was abolished with increasing concentrations of sRANKL. f) NO donors increased osteoclast formation. g) An increase in NO production coincided with pre-osteoclasts fusion. h) Inhibiting fusion decreased osteoclast formation and NO production. i) L-NMMA decreased, while NO donors increased actin …
-
Plant-derived extracellular matrix mimetic scaffolds for bone repair applications
… of factors that induce bone resorption (RANKL, sRANKL/OPG ratio and GDF15). Further, evidence suggests that osteoblasts favor kappa-carrageenan that resembles the sulfated GAG in mature bone, while stem cells favor lambda-carrageenan which resembles the sulfated GAG in bone marrow. Additionally, …
-
Serum Osteoprotegerin, a Potential Novel Marker of Systemic Inflammation: The Influence of Obesity, Insulin Sensitivity and Oral Glucose Loading on its Circulating Concentrations
… while there is no difference in TNF-α, TRAIL or sRANKL concentrations. (v) Osteoprotegerin is higher in type 2 diabetics after excluding patients with previously diagnosed vascular disease, a distinction which could not be made using traditional inflammatory markers such as IL-6, hsCRP or TNF-α. …
-
Μελέτη του συμπλέγματος rankl / οστεοπροτεγερίνης και ορμονικών παραμέτρων σε αιμοκαθαιρόμενους νεφροπαθείς ασθενείς
… parathyroid hormone (iPTH), total serum RANKL (sRANKL), osteoprotegerin (OPG), alkaline phosphatase (AP), osteocalcin (OC) and tartrate-resistant acid phosphatase (TRAP) in 104 HD patients and 40 healthy controls. 54 hemodialysis patients underwent measurement of BMD at the proximal femur and …
-
Μελέτη δεικτών οστικού μεταβολισμού, οστεοκλαστικής δραστηριότητας και αγγειογενετικών παραγόντων σε ασθενείς με συμπαγείς όγκους και οστικές μεταστάσεις
… Patients and Methods: Levels of soluble RANKL (sRANKL), OPG and RANKL/OPG ratio were assessed in 70 patients with breast (N=30), lung (N=18) and prostate (N=22) cancer with newly-diagnosed metastasis to the bone and in 40 healthy age and sex-matched volunteers. Biochemical markers of bone …
-
Εφαρμογή συστήματος διοστικών υπέρηχων στη διεπιφάνεια οστού-τένοντα και στα κατάγματα μακρών οστών. Πειραματική και κλινική μελέτη
… analyzing the serum levels of TGFb1, IGF, OPG, sRANKL, NTx and procollagen I using ELISA, and through subsequent Multiple Direction Computer Tomography. We observed statistically significant alterations in gene expression and protein level of all factors after application of LiUS in both …
-
Parenteral nutrition for premature neonates: therapeutic protocols and bone mineralization
… receptor activator of nuclear factor-kB ligand (sRANKL) reduction in Smoflipid group, indicates that n-3 PUFA-enriched PLEs might help to attenuate early bone loss in VLBW neonates. This observation conveys the idea that, in clinical practice, PLEs enriched in n-3 PUFAs may be the preferable …
Page 1 of 2